Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Are weight-loss drugs like gym memberships? The answer is worth billions
An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
Why Weight-Loss Drugs Could Be Game-Changers for Your Investment Portfolio
Weight-loss drugs are transforming both health care and Wall Street, with leading manufacturers like Eli Lilly & Co. (LLY) ...
Chelsearecord.com4h
GLP-1 Weight-loss Drugs Should be Made Affordable for all Americans
The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
RFK Jr. hails GLP-1 weight loss meds as 'miracle drugs'
Robert F. Kennedy Jr., President Trump's nominee to lead HHS, spoke highly of GLP-1 drugs at a Senate confirmation hearing ...
Euro Lost 0.29% to $1.0393 — Data Talk
Month-to-date it is up 0.36% vs the dollar --Year-to-date the euro is up 0.36% vs the dollar ...
Franco-Nevada On Track for Highest Close Since October 2023 — Data Talk
Traded as high as $137.76; highest intraday level since Oct. 25, 2023, when it hit $139.93 --Up 5.1% at today's intraday high; largest intraday percent increase since Dec. 13, 2023, when it rose as ...